ArticleBladder (San Francisco, Calif.)2025
Clinical significance of tumor location in non-muscle-invasive bladder cancer: A single-center longitudinal cohort analysis.
Article in Bladder (San Francisco, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recurrence of non-muscle-invasive bladder cancer (NMIBC) still presents a significant clinical challenge, with the contributing factors yet to be fully understood. Objective: This study explored the clinical implications of tumor location in NMIBC recurrence. Methods: An observational cohort study was conducted, including 108 NMIBC patients who experienced a total of 344 NMIBC diagnoses (both primary and recurrent) between 1999 and 2019. Clinical information was collected for primary and recurrent tumors. Tumor locations were classified into 10 categories: bladder neck (neck), dome, posterior, anterior, trigone, right, right rear, left, multiple site(s), and others. The association between tumor location and recurrence was systematically analyzed. Results: The median follow-up period lasted for 28 months (range: 2-88 months), the median recurrence interval was 13.5 months, and 44 patients (40.7%) progressed into muscle-invasive disease. Univariate analysis revealed that tumor location within the bladder significantly impacted recurrence-free interval, progression-free survival, and overall survival. Tumors situated in the bladder neck, dome, right posterior wall, and trigone demonstrated significantly shorter recurrence-free intervals, rendering these areas high-risk regions. The original tumor site was the most common relapse location, and the recurrence interval shortened as the number of recurrences increased. Over time, the recurrence pattern shifted, with tumors most frequently recurring in the left wall, multiple sites, right wall, and posterior wall. Conclusion: The findings suggest that bladder cancer most commonly recurs at the original site, with high-risk locations linked to shorter recurrent intervals and greater risks for disease progression. In addition, the recurrence interval tends to decrease with successive recurrences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.